EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

Guilhem Roubaud, Marie Kostine, Raymond S McDermott, Alice Bernard-Tessier, Xavier Maldonado, Marlon Silva, Aude Fléchon, Dominik R Berthold, Philippe Ronchin, Bertrand F Tombal, Loïc Mourey, Gwenaëlle Gravis und 8 weitere

European Journal of Cancer · 2025-03 · 218 · 115293

DOI: 10.1016/j.ejca.2025.115293 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025-03. Verfasst von Guilhem Roubaud und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institut Bergonié, Bordeaux, France. Electronic address: g.roubaud@bordeaux.unicancer.fr. Hauptthemen laut MEDLINE: Abiraterone Acetate, Antineoplastic Combined Chemotherapy Protocols, Bone Density, Prednisone. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Ipsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abiraterone AcetateAntineoplastic Combined Chemotherapy ProtocolsBone DensityPrednisoneProstatic NeoplasmsAgedAged, 80 and overHumansMaleMiddle AgedAbsorptiometry, PhotonAndrogen AntagonistsDocetaxelOsteoporosisProstatic Neoplasms, Castration-ResistantTreatment Outcome

Stichwörter der Autor:innen

Abiraterone acetate and prednisoneBone lossBone mineral densityMetastatic prostate cancer

Substanzen

Abiraterone AcetateAndrogen AntagonistsDocetaxelPrednisone

Autor:innen und Institutionen

  • Institut Bergonié, Bordeaux, France. Electronic address: g.roubaud@bordeaux.unicancer.fr.
  • University Hospital Bordeaux, France.
  • St. Vincent's University Hospital, Dublin, Ireland.
  • Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
  • Vall d'Hebron Hospital, Barcelona, Spain.
  • Centre Francois Baclesse, Caen, France.

Förderung

  • Ipsen

Zitieren

APA

Roubaud, G., Kostine, M., McDermott, R. S., Bernard-Tessier, A., Maldonado, X., Silva, M., Fléchon, A., Berthold, D. R., Ronchin, P., Tombal, B. F., Mourey, L., Gravis, G., Escande, A., Abadie-Lacourtoisie, S., Maurina, T., Climent, M. A., Ribault, H., Bossi, A., Foulon, S., & Fizazi, K. (2025). Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer, 218, 115293. https://doi.org/10.1016/j.ejca.2025.115293

Vancouver

Roubaud G, Kostine M, McDermott RS, Bernard-Tessier A, Maldonado X, Silva M, et al. Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer. 2025;218:115293. doi:10.1016/j.ejca.2025.115293

BibTeX
@article{Roubaud2025,
  author = {Roubaud, Guilhem and Kostine, Marie and McDermott, Raymond S and Bernard-Tessier, Alice and Maldonado, Xavier and Silva, Marlon and Fléchon, Aude and Berthold, Dominik R and Ronchin, Philippe and Tombal, Bertrand F and Mourey, Loïc and Gravis, Gwenaëlle and Escande, Anne and Abadie-Lacourtoisie, Sophie and Maurina, Tristan and Climent, Miguel A and Ribault, Hélène and Bossi, Alberto and Foulon, Stéphanie and Fizazi, Karim},
  title = {Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {218},
  pages = {115293},
  doi = {10.1016/j.ejca.2025.115293}
}
Kostenlos starten →